Glipizide

Glipizide is a second-generation sulfonylurea oral hypoglycemic drug. It mainly promotes the secretion of insulin by pancreatic beta cells, especially the secretion of insulin stimulated by glucose; it also enhances the action of insulin, thereby effectively reducing blood glucose concentration and glycosylated hemoglobin; it can also improve hyperlipidemia, reduce triglyceride and cholesterol levels, and increase the ratio of high-density lipoprotein cholesterol in total cholesterol; it can also inhibit platelet aggregation and promote fibrinolysis, so it may have a certain preventive and therapeutic effect on vascular diseases. ① It promotes the secretion of insulin by pancreatic beta cells, the prerequisite being that the pancreatic beta cells still have a certain function of synthesizing and secreting insulin; ② It inhibits liver glycogenolysis and gluconeogenesis by increasing portal vein insulin levels or directly acting on the liver, and reduces the production and output of glucose by the liver;

This product is mainly used for mild and moderate non-insulin-dependent patients who have not achieved good results with diet control alone; patients who have used insulin in the past but need less than 30 to 40 units per day; asymptomatic patients who still have significant hyperglycemia on the basis of diet control; and patients who are resistant to insulin. The effective rate of this drug is about 87%.

The dosage for treating adult-onset diabetes varies from person to person and should be adjusted based on regular urine and blood sugar measurements. Generally, 2.5 to 30 mg per day should be taken starting with a small amount 30 minutes before meals. If the daily dose exceeds 15 mg, it should be divided into 2 to 3 times and taken before meals.

Most insulin-dependent diabetics, those with ketosis tendency, those with severe infection, hepatic and renal insufficiency, and those allergic to this product are contraindicated. It is contraindicated for patients with diabetic ketoacidosis, diabetic hyperosmolar coma, pregnant women, those with hepatic and renal insufficiency, adrenal cortex insufficiency, and those allergic to this product.

When this product is used in combination with sulfonamides, salicylates, phenylbutazone, indomethacin, dicoumarol, monoamine oxidase inhibitors, chloramphenicol, propranolol, carboxybenzenesulfonamide, etc., it can enhance the hypoglycemic effect of this product and induce hypoglycemic reactions. Chloramphenicol, coumarins, doxycycline, muscle relaxant fenyramidol, phenylbutazone, probenecid, sulfaphenazole, etc. can inhibit the metabolism and excretion of sulfonylureas and prolong the hypoglycemic effect. Salicylic acids and sulfonamides compete with sulfonylureas for plasma protein binding. β-adrenaline, monoamine oxidase inhibitors, salicylates and antidepressants, and phenylcypromine can inhibit the formation of glucose, increase the oxidation of glucose, and stimulate the secretion of insulin. All of the above drugs can enhance the hypoglycemic effect of sulfonylureas. Sulfonylureas, especially

Keep away from light and store in a sealed container.

Dijia Pharmaceutical Group Co., Ltd.

• Founded in:

  2013-03-07

• Address:

  No. 268, Tianrun Road, Wendeng Economic Development Zone, Weihai City, Shandong Province

• Tax NO.:

  91371081062986928J

• Registered Funds:

  360.5 million yuan

• Email:

  Log in to view